Cargando…

Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing

Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-nucleoside reverse trancriptase inhibitor (NNRTI)-based r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Dieter, Garcia, Albert D., Harrigan, P. Richard, Johnston, Ian C. D., Nakasone, Tadashi, García-Lerma, J. Gerardo, Heneine, Walid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140485/
https://www.ncbi.nlm.nih.gov/pubmed/21799767
http://dx.doi.org/10.1371/journal.pone.0022019
_version_ 1782208562937724928
author Hoffmann, Dieter
Garcia, Albert D.
Harrigan, P. Richard
Johnston, Ian C. D.
Nakasone, Tadashi
García-Lerma, J. Gerardo
Heneine, Walid
author_facet Hoffmann, Dieter
Garcia, Albert D.
Harrigan, P. Richard
Johnston, Ian C. D.
Nakasone, Tadashi
García-Lerma, J. Gerardo
Heneine, Walid
author_sort Hoffmann, Dieter
collection PubMed
description Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-nucleoside reverse trancriptase inhibitor (NNRTI)-based regimens with an NRTI backbone containing lamivudine (3TC) or emtricitabine (FTC) are preferred first ART regimens. Failure with these drug combinations typically involves the selection of NNRTI- and/or 3TC/FTC- resistant viruses. Therefore, the availability of simple assays to measure both types of drug resistance is critical. We have developed a high throughput screening test for assessing enzymatic resistance of the HIV-1 RT in plasma to 3TC/FTC and NNRTIs. The test uses the sensitive “Amp-RT” assay with a newly-developed real-time PCR format to screen biochemically for drug resistance in single reactions containing either 3TC-triphosphate (3TC-TP) or nevirapine (NVP). Assay cut-offs were defined based on testing a large panel of subtype B and non-subtype B clinical samples with known genotypic profiles. Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q. The sensitivity and specificity for detecting resistance were 97.0% and 96.0% in samples with M184V, and 97.4% and 96.2% for samples with NNRTI mutations, respectively. We further demonstrate the utility of an HIV capture method in plasma by using magnetic beads coated with CD44 antibody that eliminates the need for ultracentifugation. Thus our results support the use of this simple approach for distinguishing WT from NNRTI- or 3TC/FTC-resistant viruses in clinical samples. This enzymatic testing is subtype-independent and can assist in the clinical management of diverse populations particularly in resource-limited settings.
format Online
Article
Text
id pubmed-3140485
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31404852011-07-28 Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing Hoffmann, Dieter Garcia, Albert D. Harrigan, P. Richard Johnston, Ian C. D. Nakasone, Tadashi García-Lerma, J. Gerardo Heneine, Walid PLoS One Research Article Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-nucleoside reverse trancriptase inhibitor (NNRTI)-based regimens with an NRTI backbone containing lamivudine (3TC) or emtricitabine (FTC) are preferred first ART regimens. Failure with these drug combinations typically involves the selection of NNRTI- and/or 3TC/FTC- resistant viruses. Therefore, the availability of simple assays to measure both types of drug resistance is critical. We have developed a high throughput screening test for assessing enzymatic resistance of the HIV-1 RT in plasma to 3TC/FTC and NNRTIs. The test uses the sensitive “Amp-RT” assay with a newly-developed real-time PCR format to screen biochemically for drug resistance in single reactions containing either 3TC-triphosphate (3TC-TP) or nevirapine (NVP). Assay cut-offs were defined based on testing a large panel of subtype B and non-subtype B clinical samples with known genotypic profiles. Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q. The sensitivity and specificity for detecting resistance were 97.0% and 96.0% in samples with M184V, and 97.4% and 96.2% for samples with NNRTI mutations, respectively. We further demonstrate the utility of an HIV capture method in plasma by using magnetic beads coated with CD44 antibody that eliminates the need for ultracentifugation. Thus our results support the use of this simple approach for distinguishing WT from NNRTI- or 3TC/FTC-resistant viruses in clinical samples. This enzymatic testing is subtype-independent and can assist in the clinical management of diverse populations particularly in resource-limited settings. Public Library of Science 2011-07-20 /pmc/articles/PMC3140485/ /pubmed/21799767 http://dx.doi.org/10.1371/journal.pone.0022019 Text en This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Hoffmann, Dieter
Garcia, Albert D.
Harrigan, P. Richard
Johnston, Ian C. D.
Nakasone, Tadashi
García-Lerma, J. Gerardo
Heneine, Walid
Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing
title Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing
title_full Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing
title_fullStr Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing
title_full_unstemmed Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing
title_short Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing
title_sort measuring enzymatic hiv-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to hiv-1 drug-resistance testing
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140485/
https://www.ncbi.nlm.nih.gov/pubmed/21799767
http://dx.doi.org/10.1371/journal.pone.0022019
work_keys_str_mv AT hoffmanndieter measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting
AT garciaalbertd measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting
AT harriganprichard measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting
AT johnstoniancd measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting
AT nakasonetadashi measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting
AT garcialermajgerardo measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting
AT heneinewalid measuringenzymatichiv1susceptibilitytotworeversetranscriptaseinhibitorsasarapidandsimpleapproachtohiv1drugresistancetesting